Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
9.50M | 8.95M | 14.70M | 3.90M | 773.00K | Gross Profit |
9.16M | 8.27M | 13.97M | 2.47M | 388.00K | EBIT |
-21.48M | -24.73M | -22.52M | -49.21M | -26.45M | EBITDA |
-21.48M | -24.04M | -21.79M | -48.34M | -24.41M | Net Income Common Stockholders |
-18.61M | -21.49M | -26.35M | -38.56M | -20.68M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
47.80M | 35.49M | 57.88M | 58.36M | 41.56M | Total Assets |
113.22M | 101.02M | 123.66M | 174.54M | 107.95M | Total Debt |
2.51M | 2.95M | 3.90M | 2.80M | 3.30M | Net Debt |
-43.27M | -32.49M | -7.46M | -52.94M | -29.28M | Total Liabilities |
36.21M | 39.00M | 51.73M | 83.65M | 12.82M | Stockholders Equity |
77.01M | 63.42M | 73.34M | 92.22M | 96.20M |
Cash Flow | Free Cash Flow | |||
-23.09M | -29.24M | 646.00K | -23.91M | -19.82M | Operating Cash Flow |
-23.09M | -28.57M | 1.06M | -23.56M | -19.75M | Investing Cash Flow |
-2.31M | 46.45M | -46.16M | 9.74M | 13.04M | Financing Cash Flow |
35.86M | 6.42M | 1.63M | 36.93M | 29.86M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
49 Neutral | $6.86B | 0.03 | -54.79% | 2.48% | 24.62% | -2.84% | |
46 Neutral | $1.66B | ― | -21.26% | ― | ― | ― | |
45 Neutral | $118.75M | ― | -26.25% | ― | 6.19% | 22.05% | |
44 Neutral | $23.46M | ― | -221.25% | ― | -59.08% | 18.99% | |
42 Neutral | $36.53M | ― | -270.20% | ― | 144.50% | -141.91% | |
42 Neutral | $107.89M | ― | -54.21% | ― | -78.55% | -0.92% |
Lineage Cell Therapeutics announced the closing of the second tranche of its registered direct offering on January 27, 2025, following shareholder approval. The company has received $30 million in gross proceeds so far, with the potential for an additional $36 million from clinical milestone-linked warrants. The funds will be used for working capital, general corporate purposes, research, and development.